JP2020521726A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521726A5 JP2020521726A5 JP2019559117A JP2019559117A JP2020521726A5 JP 2020521726 A5 JP2020521726 A5 JP 2020521726A5 JP 2019559117 A JP2019559117 A JP 2019559117A JP 2019559117 A JP2019559117 A JP 2019559117A JP 2020521726 A5 JP2020521726 A5 JP 2020521726A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- achieves
- dosage form
- daily dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126062 Compound A Drugs 0.000 claims description 33
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000006186 oral dosage form Substances 0.000 claims description 10
- VLCMRTMCMQJSKM-UHFFFAOYSA-N phenyl-[4-phenyl-8-(trifluoromethyl)quinolin-3-yl]methanone Chemical compound C=1C=CC=CC=1C(=O)C1=CN=C2C(C(F)(F)F)=CC=CC2=C1C1=CC=CC=C1 VLCMRTMCMQJSKM-UHFFFAOYSA-N 0.000 claims description 9
- -1 2-methoxy-3,5-dimethylpyridin-4-yl Chemical group 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 description 5
- CKJDCNZBABIEBZ-HNNXBMFYSA-N Cc(c(-c(cc1)cc(N2)c1-c([n]([C@@H]1COCC1)nc1)c1C2=O)c1C)cnc1OC Chemical compound Cc(c(-c(cc1)cc(N2)c1-c([n]([C@@H]1COCC1)nc1)c1C2=O)c1C)cnc1OC CKJDCNZBABIEBZ-HNNXBMFYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513690P | 2017-06-01 | 2017-06-01 | |
| US62/513,690 | 2017-06-01 | ||
| PCT/JP2018/020643 WO2018221546A1 (en) | 2017-06-01 | 2018-05-30 | Pharmaceutical composition comprising pde9 inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020521726A JP2020521726A (ja) | 2020-07-27 |
| JP2020521726A5 true JP2020521726A5 (cg-RX-API-DMAC7.html) | 2021-07-26 |
| JP7293129B2 JP7293129B2 (ja) | 2023-06-19 |
Family
ID=64455959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559117A Active JP7293129B2 (ja) | 2017-06-01 | 2018-05-30 | Pde9阻害剤を含む医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11484502B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3630113A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7293129B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200010211A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116585316A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018276566A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019023557A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3059539A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019013198A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019135261A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201909359YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018221546A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200010220A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제 |
| BR112019023569A2 (pt) | 2017-06-01 | 2020-06-02 | Eisai R&D Management Co., Ltd. | Agente terapêutico da demência combinando derivados de pirazoloquinolina e donepezila |
| JP7177772B2 (ja) | 2017-06-01 | 2022-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤 |
| KR20240101561A (ko) | 2021-10-14 | 2024-07-02 | 인사이트 코포레이션 | Kras의 저해제로서의 퀴놀린 화합물 |
| WO2024107445A1 (en) * | 2022-11-15 | 2024-05-23 | Freedom Biosciences, Inc. | Enhancement of the efficacy of serotonergic psychedelic drugs in the treatment or prevention of certain neuropsychiatric disorders through inhibition of type-9 phosphodiesterases |
| CN119302958B (zh) * | 2023-12-01 | 2025-10-21 | 郑州大学第一附属医院 | 含有bay 73-6691或其衍生物的药物制剂在制备治疗脑损伤疾病药物中的应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5318759A (en) | 1976-08-02 | 1978-02-21 | Nisshin Oil Mills Ltd | Method of making fried beancurd |
| JPH05132484A (ja) | 1991-04-26 | 1993-05-28 | Otsuka Pharmaceut Factory Inc | ピラゾロキノリン及びピラゾロナフチリジン誘導体 |
| DE69518075T2 (de) | 1994-05-24 | 2001-03-22 | F. Hoffmann-La Roche Ag, Basel | Tricyclische dicarbonylderivate |
| DE19642591A1 (de) | 1996-10-15 | 1998-04-16 | Basf Ag | Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung |
| HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| EP1537106A1 (en) | 2002-08-07 | 2005-06-08 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds |
| DE10238722A1 (de) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE102004004142A1 (de) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine |
| RU2426734C2 (ru) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
| US20060035920A1 (en) | 2004-05-28 | 2006-02-16 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| JP2006045118A (ja) | 2004-08-04 | 2006-02-16 | Mochida Pharmaceut Co Ltd | 新規ピラゾロキノロン誘導体 |
| WO2007032466A1 (ja) | 2005-09-15 | 2007-03-22 | Aska Pharmaceutical Co., Ltd. | 複素環化合物、その製造方法並びに用途 |
| TW200808741A (en) | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
| WO2007146073A2 (en) | 2006-06-09 | 2007-12-21 | Wyeth | Method for enhancing cognitive function |
| WO2008072779A1 (ja) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | キノキサリン誘導体 |
| AU2007332439A1 (en) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | Therapeutic agent for urinary tract disease |
| PT2152712E (pt) | 2007-05-11 | 2012-02-29 | Pfizer | Compostos amino-heterocíclicos |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| CN102143965A (zh) | 2008-09-08 | 2011-08-03 | 贝林格尔.英格海姆国际有限公司 | 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途 |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
| AU2010219598A1 (en) | 2009-03-05 | 2011-09-22 | Astellas Pharma Inc. | Quinoxaline compounds |
| UY32531A (es) | 2009-03-31 | 2010-10-29 | Boehringer Ingelheim Int | Nuevos compuestos para el tratamiento de trastornos del snc |
| LT2419104T (lt) | 2009-04-13 | 2018-02-12 | Theravance Biopharma R&D Ip, Llc | 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui |
| US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
| BR112013003097B1 (pt) | 2010-08-12 | 2021-03-16 | Boehringer Ingelheim International Gmbh | 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica |
| ES2583528T3 (es) | 2010-09-07 | 2016-09-21 | Astellas Pharma Inc. | Compuesto de pirazoloquinolina |
| US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| JP6042060B2 (ja) | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
| SI2573073T1 (sl) | 2011-09-26 | 2015-02-27 | Sanofi | Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba |
| JP5938299B2 (ja) | 2011-10-05 | 2016-06-22 | ダイセルポリマー株式会社 | 繊維強化樹脂組成物 |
| CN103930423B (zh) * | 2011-10-07 | 2015-09-16 | 卫材Rd管理有限公司 | 吡唑并喹啉衍生物 |
| JP5666755B1 (ja) | 2013-04-05 | 2015-02-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体の塩およびその結晶 |
| WO2016179569A1 (en) | 2015-05-07 | 2016-11-10 | Axovant Sciences Ltd. | Compositions and methods of treating a neurodegenerative disease |
| KR20200010220A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제 |
| JP7177772B2 (ja) | 2017-06-01 | 2022-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤 |
| BR112019023569A2 (pt) | 2017-06-01 | 2020-06-02 | Eisai R&D Management Co., Ltd. | Agente terapêutico da demência combinando derivados de pirazoloquinolina e donepezila |
-
2018
- 2018-05-30 CN CN202310559688.6A patent/CN116585316A/zh active Pending
- 2018-05-30 MX MX2019013198A patent/MX2019013198A/es unknown
- 2018-05-30 RU RU2019135261A patent/RU2019135261A/ru unknown
- 2018-05-30 WO PCT/JP2018/020643 patent/WO2018221546A1/en not_active Ceased
- 2018-05-30 SG SG11201909359Y patent/SG11201909359YA/en unknown
- 2018-05-30 AU AU2018276566A patent/AU2018276566A1/en not_active Abandoned
- 2018-05-30 CN CN201880027744.9A patent/CN110545812A/zh active Pending
- 2018-05-30 KR KR1020197032163A patent/KR20200010211A/ko not_active Ceased
- 2018-05-30 BR BR112019023557-4A patent/BR112019023557A2/pt not_active IP Right Cessation
- 2018-05-30 JP JP2019559117A patent/JP7293129B2/ja active Active
- 2018-05-30 EP EP18809656.4A patent/EP3630113A4/en active Pending
- 2018-05-30 CA CA3059539A patent/CA3059539A1/en active Pending
- 2018-05-30 US US16/609,514 patent/US11484502B2/en active Active
-
2022
- 2022-06-03 US US17/831,863 patent/US20220378706A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016226006B2 (en) | Method of treatment with tradipitant | |
| CN109890391B (zh) | 痴呆症的治疗 | |
| JP2014517050A5 (cg-RX-API-DMAC7.html) | ||
| JP2022110143A5 (cg-RX-API-DMAC7.html) | ||
| JP2013501731A5 (cg-RX-API-DMAC7.html) | ||
| JP2017506624A5 (cg-RX-API-DMAC7.html) | ||
| IL270395B (en) | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil | |
| FI3856341T3 (fi) | (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä | |
| JP2020521797A5 (cg-RX-API-DMAC7.html) | ||
| RU2019135261A (ru) | Фармацевтическая композиция, содержащая ингибитор pde9 | |
| JP5738397B2 (ja) | 帯状ヘルペス疾患の治療用のオピオイド受容体拮抗薬(ナルトレキソン) | |
| CN110603039B (zh) | 组合吡唑并喹啉衍生物和美金刚的痴呆治疗剂 | |
| JP2014513705A (ja) | 進行性固形腫瘍の治療方法 | |
| EP4520394A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2011518168A5 (cg-RX-API-DMAC7.html) | ||
| JP2014517078A5 (cg-RX-API-DMAC7.html) | ||
| JP2015516980A5 (cg-RX-API-DMAC7.html) | ||
| JP2021167361A (ja) | 神経変性障害を処置するための方法 | |
| JP2022514561A5 (cg-RX-API-DMAC7.html) | ||
| US20060148802A1 (en) | Use of compounds that stimulate cgmp | |
| WO2010110428A1 (ja) | 掻痒の予防及び/または治療剤 | |
| FI3909568T3 (fi) | Profylaktinen tai terapeuttinen lääke neurodegeneratiivisiin tauteihin | |
| JP2503571B2 (ja) | 脳循環代謝改善剤 | |
| JP2021091608A5 (cg-RX-API-DMAC7.html) | ||
| IL273543B1 (en) | New treatment of sma |